N-tert-butylpropanediamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-tert-butylpropanediamide
• 英文别名: N-t-butylmalonamide；N'-tert-butylpropanediamide
• 化学式: C₇H₁₄N₂O₂
• 分子量: 158.2
• InChiKey: WJBOQZMBTCBDJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  72.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  溴代叔丁烷 、 丙二酰胺 在 羰基镁 作用下， 反应 2.0h， 以64%的产率得到N-tert-butylpropanediamide
  参考文献：
  名称：

  Synthesis of N-tert-butyl amides by reaction of tert-butyl bromide with amides in the presence of manganese compounds

  摘要：

  DOI：

  10.1134/s1070428015100255

文献信息

• Substituted N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
  申请人：PHENEX DISCOVERY VERWALTUNGS-GMBH

  公开号：US11078168B2

  公开（公告）日：2021-08-03

  The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.

  本发明提供了吲哚胺 2,3-二氧化酶（IDO1）的调节剂及其在预防和/或治疗 IDO1 介导的疾病中的用途。具体而言，本发明提供了符合式（I）的化合物及其对映体、非对映体、同分异构体或药学上可接受的盐。
• CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY
  申请人：GENENTECH, INC.

  公开号：EP1817059A2

  公开（公告）日：2007-08-15
• Antibody drug conjugates and methods
  申请人：Gazzard J. Lewis

  公开号：US20070134243A1

  公开（公告）日：2007-06-14

  The invention relates to antibody drug conjugate (ADC) compounds represented by Formula I: Ab-(L-D) p I where one or more 1,8 bis-naphthalimide drug moieties (D) having Formulas IIa and IIb are covalently linked by a linker (L) to an antibody (Ab). The invention also relates to pharmaceutical compositions comprising an effective amount of a Formula I ADC for treatment of hyperproliferative disorders and other disorders. The invention also relates to methods for killing or inhibiting the multiplication of a tumor cell or cancer cell including administering to a patient an effective amount of a Formula I ADC.
• SUBSTITUTED N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
  申请人：PHENEX DISCOVERY VERWALTUNGS-GMBH

  公开号：US20190292160A1

  公开（公告）日：2019-09-26

  The invention provides modulators of indoleamine 2,3-dioxygenase (IDO1) and their use in the prophylaxis and/or treatment of IDO1-mediated diseases. Specifically, the present invention provides compounds according to Formula (I) an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof.
• US5607943A
  申请人：——

  公开号：US5607943A

  公开（公告）日：1997-03-04